De Novo MET-amplified NSCLC treated with savolitinib achieved remarkable tumor regression: a case report and review of literature
Abstract Primary MET amplification is an infrequent tumorigenic driver gene alteration identified in pulmonary neoplasms.Data on the effectiveness of MET-tyrosine kinase inhibitor (TKI) therapy in de novo MET amplification are relatively scarce, and there remains a dearth of empirical evidence supporting the use of precision therapy as first-line t